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Abstract
Substance P (SP) is a prototypical neuropeptide with roles in pain and inflammation. Numerous mechanisms regulate
endogenous SP levels, including the differential expression of SP mRNA and the controlled secretion of SP from neurons.
Proteolysis has long been suspected to regulate extracellular SP concentrations but data in support of this hypothesis is
scarce. Here, we provide evidence that proteolysis controls SP levels in the spinal cord. Using peptidomics to detect and
quantify endogenous SP fragments, we identify the primary SP cleavage site as the C-terminal side of the ninth residue of
SP. If blocking this pathway increases SP levels, then proteolysis controls SP concentration. We performed a targeted
chemical screen using spinal cord lysates as a proxy for the endogenous metabolic environment and identified GM6001
(galardin, ilomastat) as a potent inhibitor of the SP 1–9-producing activity present in the tissue. Administration of GM6001 to
mice results in a greater-than-three-fold increase in the spinal cord levels of SP, which validates the hypothesis that
proteolysis controls physiological SP levels.
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Introduction
A member of the tachykinin family of neuropeptides, substance
P (SP) is an amidated undecapeptide (Fig. 1) that is widely
expressed in the central and peripheral nervous systems [1] of
mammals and functions as a neurotransmitter and neuromodu-
lator [2]. It participates in a host of fundamentally and
biomedically important physiological processes, including pain
transmission [3–5], inflammation [6,7], sleep [8], learning and
memory [9,10], depression and affective mood disorders [11–13],
opioid dependence [14–16] and apoptosis [17,18]. This broad
function profile has driven interest in uncovering the mechanisms
that control SP’s activity.
Several mechanisms have been definitively shown to regulate
SP. These include the differential expression of SP mRNA [19–21]
and the controlled release of SP from neuron terminals [22]. In
view of the well-established role of proteolysis in regulating the
activity of certain other bioactive peptides, such as GLP-1 [23] and
PHI-27 [24], researchers have postulated that proteolysis of SP in
the extracellular space also controls SP levels. A multitude of in
vitro and pseudo in vivo studies indicate SP-degrading activity is
abundant in mammalian nervous tissue lend plausibility to this
hypothesis [25,26]. However, one cannot conclude from the mere
presence of SP-degrading activity in SP-containing tissues that
proteolysis controls SP levels because it is possible that the
enzymes responsible for the observed activities do not physically
contact endogenous SP in the cell or are otherwise prevented from
acting on the peptide (e.g., through protein-protein interactions
that are not recapitulated in the test tube). Furthermore, even if
one or more of the observed activities acts on SP in vivo, it doesn’t
follow that they control the peptide’s levels: the cleavage events
may destroy only a small fraction of the total SP present in the
extracellular space and therefore not appreciably impact SP
concentration. Thus, metabolic studies are not sufficient to
establish proteolysis as a mechanism of SP regulation.
One way to definitively determine that proteolysis regulates SP
would be to block a proteolytic pathway in vivo and show that SP
levels change as a result. With this goal, many researchers have
sought to identify the enzymes responsible for the SP-degrading
activities observed in the aforementioned in vitro studies [27–33],
the idea being that targeted pharmacological or genetic knock-
down studies could then be used to probe an SP-degrading
pathway. However, to date, no enzyme has been proven to
degrade SP in vivo and no studies have shown that blocking a
proteolytic pathway can modulate SP levels.
Recognizing that enzyme identification approaches are very
time consuming given their reliance on extensive biochemical
purification and confirmatory studies, we wondered whether there
is an easier path to evaluating the hypothesis that proteolysis
regulates SP. To this end, we devised a strategy that couples in vivo
peptidomics with in vitro chemical screens to rapidly discover
physiologically relevant proteolytic pathways and identify probes
that can be used to block them. Focusing our efforts on the spinal
cord, where SP executes its most widely studied function of
transmitting pain signals from the periphery into the CNS [34], we
used this method to determine that a major endogenous SP-
degrading pathway cleaves SP at the C-terminal side of residue
nine and identify a peptidase inhibitor (GM6001) capable of
blocking this pathway. When we injected mice with this
compound we observed a greater-than-three-fold increase in
PLOS ONE | www.plosone.org 1 July 2013 | Volume 8 | Issue 7 | e68638endogenous SP levels, thus proving that SP levels are controlled by
proteolysis.
Materials and Methods
Compounds
Mouse SP was purchased from Anaspec, Inc. A protease
inhibitor panel was obtained from Sigma Aldrich Inc.
Peptide synthesis
Heavy-labeled SP1–7 (Pro containing five
13C and one
15N),
SP1–9 (Phe containing eight
2H), and SP (Leu containing ten
2H)
were synthesized manually using FMOC chemistry for solid-phase
peptide synthesis. Crude peptides were purified by RP-HPLC
(Shimadzu) using a C18 column (150620 mm, 10 mm particle
size, Higgins Analytical). The HPLC gradient varied depending on
the peptide (Mobile Phase A: 99% H2O, 1% Acetonitrile, 0.1%
TFA; Mobile Phase B: 90% Acetonitrile, 10% H2O, 0.07% TFA).
HPLC fractions were analyzed for purity by MALDI-TOF
(Waters) using a-cyano-4-hydroxycinnamic acid as the matrix.
Pure fractions were combined and lyophilized. Concentrations of
the purified peptides were determined by UV-vis using the
extinction coefficient for phenylalanine.
Animal studies
Wild type (C57BL/6) mice used in this study were either
purchased (Jackson Labs) or taken from a breeding colony. Nep
–/–
mice were obtained from Craig Gerard at Children’s Hospital
(Boston, MA) and were on a C57BL/6 background [35]. Mice in
these studies were not littermates from het x het crosses, but were
obtained from separate colonies of Nep
–/– and WT mice. All mice
used in this study ranged from 3 to 6 months old. Animals were
kept on a 12-h light, 12-h dark schedule and fed ad libitum. For
spinal cord tissue collection, animals were euthanized with CO2,
their tissue dissected, flash frozen with liquid N2, and stored at
280uC. All animal care and use procedures were in strict
accordance with the standing committee on the use of animals in
research and teaching at Harvard University and the National
Institute of Health guidelines for the humane treatment of
laboratory animals. The Harvard institutional Animal Care and
Use Committee (IACUC) or ethics committee specifically
approved this study and the protocol number is 26–06.
Isolation of physiological peptides from tissue
Tissue peptide isolation and fractionation were previously
described [24,36,37]. Briefly, frozen spinal cords were placed in
500 mL of water and boiled for 10 minutes to inactivate any
residual proteolytic activity prior to tissue homogenization. The
aqueous fraction was separated and saved, and the tissue was
dounce-homogenized in ice-cold 0.25% aqueous acetic acid. The
aqueous fraction and the homogenate were combined and
centrifuged at 20,0006g for 20 min at 4uC. The supernatant
was then sent through a 10 kDa molecular weight cut-off filter
(VWR Modified PES) to enrich the peptide pool and then a C18
Sep Pak cartridge (HLB 1cc; 30 mg, Oasis) to desalt the sample.
The peptides were then eluted with 1 mL of 70:30 H2O/ACN
and concentrated under vacuum using a speed vac prior to
fractionation by strong cation exchange (SCX).
Figure 1. C-terminal processing is the primary mode of SP degradation. A) An integrated approach that combines chemical screening and
peptide profiling provides a new strategy to determine whether proteolysis plays a role in the regulation of endogenous SP levels. B) Initial
experiments begin in tissue lysates and the data clearly shows that SP is processed by membrane proteases to generate a series of C-terminally
truncated fragments, while the soluble proteome has little impact on SP processing.
doi:10.1371/journal.pone.0068638.g001
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TM column
(20062.1mm, 5 mm, 300 A ˚; PolyLC INC.) connected to an
Agilent Technologies 1200 series LC. All runs were operated at
0.3 mL/min. The SCX buffers (prepared with MS quality water)
consisted of: A) 7 mM KH2PO4, pH 2.6, 25% ACN (vol/vol); B)
40 mM KCl, 7 mM KH2PO4, pH 2.6, 25% ACN (vol/vol); C)
100 mM KCl, 7 mM KH2PO4, pH 2.6, 25% ACN (vol/vol); D)
600 mM KCl, 7 mM KH2PO4, pH 2.6, 25% ACN (vol/vol).
Prior to the SCX runs, all samples (N=4) were dissolved in
900 mL buffer A (1 mL sample loop). A step-gradient was applied
that included 60 min with Buffer A, 60 min with Buffer B, 60 min
with Buffer C, and 60 min with Buffer D, with 1 min transitions
between the different buffer conditions. Fractions were collected
separately for each of the different buffer conditions (e.g., a buffer
A fraction, a buffer B fraction, and so on). Fraction C was isolated
because SP and the primary peptide products cleaved at the C-
terminus are expected to be +3 charged at pH 2.6. This fraction
was applied to a C18 Sep Pak cartridge, washed with water to
desalt the samples, and then eluted with 1 mL of 70:30 H2O/
ACN and concentrated using a speed vac. It is important to note
that the Met on SP becomes nearly 100% oxidized following SCX.
The peptide samples were dissolved in 0.1% aqueous formic acid
(50 mg tissue/20 mL), normalized according to the original tissue
weight, prior to LC-MS analysis.
LC-MS/MS experiments to detect SP peptide fragments
Fractionated spinal cord samples (N=4) were analyzed using a
nano flow LC (Nano LC-2D, Eksigent Technologies) system
coupled to a linear ion trap mass spectrometer (LTQ, Thermo-
Finnigan) following a 10 uL injection. The analytical column (Self-
pack picofrit column, 75 mm ID, New Objective) was packed
15 cm with 3 mm C18 (Magic C18 AQ 200A 3U, Michrom
Bioresources Inc). The trap column was obtained pre-packed from
New Objective Inc. (Integrafrit sample trap, C18 5 mm, 100 mm
column ID). The samples were trapped at an isocratic flow rate of
2 ml/min for 10 minutes and eluted at a flow rate of 300 nl/min
via a mobile phase gradient of 2–50% B in 180 min (Mobile Phase
A: 0.1% formic acid in water, Mobile Phase B: 0.1% formic acid in
acetonitrile). The peptides were detected in the positive mode and
the mass range for data acquisition was set from m/z 400–1600.
The data were collected in Top 6 MS2 mode (N=4) with the
dynamic exclusion set for 30s, the exclusion size list set to 200, and
the normalized collision energy for CID set to 35%. The capillary
spray voltage was set to 2.5 kV. All experiments were repeated
multiple times to ensure reproducibility.
Peptide identification was performed via two methods using the
SEQUEST algorithm. The first method applied a differential
modification of methionine to its sulfoxide. The uniprotmus_frc.-
fasta mouse database, concatenated to a reversed decoy database,
served to estimate a false discovery rate (FDR). Peptides were
accepted within 1 Da of the expected mass, meeting a series of
custom filters on ScoreFinal (Sf), 210 Log P, and charge state that
attained an average peptide FDR of ,2% across data sets.
Manual inspection of spectra, FDR calculation, and protein
inference were performed in Proteomics Browser Suite 2.23
(ThermoFisher Scientific).
In the second method that has been previously described
[24,37], we used an algorithm written in-house that reveals related
MSMS spectra (MuQuest; Harvard Proteomics Browser Suite).
To analyze the spinal cord proteome to search for SP fragments,
we used the MSMS data from in vitro membrane lysate
experiments. MuQuest is then applied to compare the in vitro
MSMS spectra with those of the in vivo data set to determine which
in vitro MSMS spectra (which peptides) are present in the in vivo
samples. The output files are filtered based on charge state, mass
to charge values, and statistical scores. All SP related peptides that
were identified in these data were confirmed by analysis of the
extracted ion chromatograms (EICs) for these hits.
Isotope dilution MS (IDMS) to determine endogenous
levels of SP and its N-terminal peptide fragments
The heavy-label versions of SP1–7,S P 1–9, and SP were spiked
into spinal cord samples (N=4) at the beginning of the peptide
isolation process. After fine tuning the amount of spiked peptides,
it was determined that a final concentration of 100 fmol/mLo f
SP1–7 and SP and 25 fmol/mLo fS P 1–9 would lead to adequate
measurements of the peptides using Top 6 MS/MS. A compar-
ison was made of the integrated area for specific, corresponding
fragments of the +2 charge state of the endogenous and heavy
labeled peptides detected in the positive mode. The mass range for
data acquisition was set from m/z 400–700. The peptide levels
were measured in pmol peptide/g of tissue. All experiments were
repeated multiple times to ensure reproducibility.
Monitoring N-terminal SP fragment formation in spinal
cord lysates
Three mouse spinal cords were dounce homogenized in 1.1 mL
phosphate buffered saline (PBS) on ice and then sonicated for 15 s
at 4uC. Tissue debris was separated by centrifuging the sample at
5,0006g for 20 min at 4uC. The soluble fraction was collected
after ultracentrifugation of the sample at 55,0006g for 1 h at 4uC.
The membrane pellet that remained was washed 3x with 600 mL
PBS. The pellet was then suspended in 100 mL PBS by sonication
for 5 s at 4uC. The sample was ultracentrifugation at 55,0006g for
1 h at 4uC and the supernatant was separated as a wash
membrane sample. The pellet was suspended in 100 mLo f
1 mM sodium deoxycholate (Alfa Aesar) by sonication for 5 s at
4uC then stirred for 30 min at 4uC. Ultracentrifugation of the
sample at 55,0006g for 1 h at 4uC separated the supernatant as a
1 mM deoxycholate-solubilized membrane fraction. The remain-
ing pellet was washed 3x with 600 mL 1 mM deoxycholate
solution. The pellet was subsequently suspended in 4, 12, and
24 mM deoxycholate following the same cycle. The final pellet
was suspended in 100 mL PBS. The protein content in the soluble
and membrane lysates was quantified by the Bradford assay. SP
(100 mM) was incubated in 1 mg/mL soluble and membrane
lysates diluted in 20 mM ammonium bicarbonate, pH 7.34 buffer
for 1 h (determined to be the optimal incubation time) at 37uC.
The reactions were quenched with neat formic acid and speed vac
dried. The samples were dissolved in 0.1% formic acid (aq) and
analyzed by MALDI-TOF MS for SP-degrading activity (i.e.
formation of SP1–7 and SP1–9) using the method outlined in
‘‘MALDI-TOF MS and LC-MS/MS analysis of in vitro peptides’’
section. All in vitro degradation experiments were performed using
the same bicarbonate buffer and quenching solutions. Experiments
performed with lysates boiled for 5 minutes, served as a negative
control.
Developing a candidate list for the SP degrading
enzymes responsible for the formation of SP1–9
The MEROPS database was utilized to devise a candidate list
for the enzymes that could cleave SP, forming SP1–9 in mice [38].
The candidate list was narrowed based on protein abundance
using the following databases: www.brain-map.org; https:// www.
nextbio.com/b/nextbio.nb.
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Western blotting was used to detect endothelin-converting
enzyme 2 (ECE2) (Proteintech Group Inc.; rabbit polyclonal) and
pitrilysin (Proteintech Group Inc.; rabbit polyclonal) in the mouse
spinal cord membrane lysates prepared by deoxycholate solubi-
lization.
Protease inhibitor studies using general enzyme class
inhibitors
The membrane fraction of spinal cord lysates (1 mg/mL) were
pre-incubated at 37uC for 30 minutes separately with each of the
following inhibitors (N=4): 10 mM E-64 (cysteine protease),
1 mM iodoacetamide (cysteine protease), 1 mM o-phenanthroline
(metalloprotease), 10 mM pepstatin A (aspartyl protease), 1 mM
phenylmethylsulfonyl fluoride (PMSF, serine protease), 1 mM
diisopropylfluorophosphate (serine protease), and vehicle (PBS
with DMSO for 5% DMSO final concentration in reaction). After
the pre-incubation with each inhibitor, SP was added to 100 mM
final concentration. The reactions proceeded at 37uC for 1 h.
Dried samples were dissolved in 0.1% formic acid (aq) and
analyzed by LC-MS/MS for SP-degrading activity (i.e. formation
of SP1–7 and SP1–9) using the method outlined in ‘‘MALDI-TOF
MS and LC-MS/MS analysis of in vitro peptides’’ section.
Protease inhibitor studies using metalloprotease specific
enzyme class inhibitors
The membrane fraction of spinal cord lysates (1 mg/mL) were
pre-incubated at 37uC for 30 minutes separately with each of the
following inhibitors (N=4): SM-19712 (ECE1), phosphoramidon
(neprilysin; ECE2), MMP9 inhibitor, TIMP2 (MMP inhibitor),
GM6001 (MMP and neprilysin broad inhibitor), chymostatin
(pitrilysin), captopril (ACE), enalaprilat (ACE), actinonin (Meprin
1A), and vehicle (PBS with DMSO for 5% DMSO final
concentration in reaction). All inhibitors were present at 100 mM
except for TIMP2, which was present at 4 mM. After the pre-
incubation with each inhibitor, either SP or SP1–9 was added to
100 mM final concentration. The reactions proceeded at 37uC for
1 h. Dried samples were dissolved in 0.1% formic acid (aq) and
analyzed by LC-MS/MS for SP or SP1–9-degrading activity. The
same comparative reactions were performed with the deoxycho-
late-solubilized membrane fractions but only with the GM6001
inhibitor.
In vivo and in vitro comparative study of SP degradation
in WT and Nep
–/– mice spinal cord tissue
The levels of SP in WT and Nep
–/– mice spinal cord tissue
(N=4) were compared by IDMS using Top 6 MS/MS as
described previously. The degradation of SP was compared in
1 mg/mL WT and Nep
–/– mice spinal cord membrane lysates
using LC-MS/MS analysis following the above method.
MALDI-TOF MS and LC-MS/MS analysis of in vitro
peptides
MALDI-TOF MS was performed with a-cyano-4-hydroxycin-
namic acid as the matrix using 2 mLo fa5 0mM reconstituted
degradation reaction solution (based on initial SP quantities). Data
were acquired on a Waters MALDI micro MX instrument
operated in reflectron positive mode.
For LC-MS analysis, an Agilent 6220 LC-ESI-TOF instrument
was used in the positive mode. A Bio-Bond C18 (5 mm,
15062.1 mm) column was used together with a precolumn
(C18, 3.5 mm, 2620 mm). Following injection of 25 mLo f5mM
solutions, the samples were trapped at an isocratic flow rate of
0.1 ml/min for five minutes and eluted at a flow rate of 0.25 mL/
min via a mobile phase gradient of 2–100% B in 40 min (Mobile
Phase A: 0.1% formic acid in water, Mobile Phase B: 0.1% formic
acid in acetonitrile). MS analysis was performed with an
electrospray ionization (ESI) source. The capillary voltage was
set at 4.0 kV and the fragmentor voltage to 100 V. The drying gas
temperature was 350uC, the drying gas flow rate was 10 L/min,
and the nebulizer pressure was 45 psi. Data was collected in the
centroid mode using a mass range of 100–500 Da. The peptides
were analyzed by mass extraction of the +3 charge state.
Endogenous GM6001 experiments
For GM6001 injection experiments, 3–4 month old female WT
mice (N=4) were fasted overnight. GM6001 was dissolved at a
high concentration in DMSO. Intraperitoneal (i.p.) injections were
performed with a 10 mL/g injection of either vehicle (5% DMSO,
95% saline) or 10 mg/mL GM6001 in 5% DMSO, 95% saline for
a final dose of 100 mg/kg GM6001. Mice were allowed to return
to their cages for three hours and then spinal cords were isolated as
described in the ‘Animal studies’ section. IDMS was used to
measure differences in the levels of SP in the inhibitor treated and
untreated samples.
Data
All data will be made available upon request.
Results
Proteolysis of SP occurs primarily through C-terminal
processing
To determine the candidate proteolytic pathway or pathways
for SP degradation in the spinal cord, we separated tissue lysates
from mouse spinal cords into membrane and soluble fractions,
incubated them with full-length SP for varying lengths of time (15,
60, 240 min) and then analyzed the quenched reactions by
MALDI mass spectrometry to identify any SP fragments that had
been produced. No discernable fragments appeared in the soluble
fraction, while ions corresponding to SP1–10,S P 1–9,S P 1–8, and
SP1–7 were all produced in the membrane fraction (Fig. 1). These
sequence assignments were validated by liquid chromatography-
tandem mass spectrometry (LC-MS/MS) [39]. The data indicates
that the primary SP-degrading activity in spinal cord resides in the
membrane fraction and that proteolysis of SP occurs through C-
terminal processing, which is consistent with previous in vitro lysate
experiments [32,40,41].
SP1–9 and SP1–7 are endogenous metabolites of SP
Lysate experiments are imperfect because the compartmental-
ization of a tissue is disrupted, which can lead to the production of
SP fragments that are not physiologically relevant. Therefore, we
complement these lysate experiments with LC-MS/MS experi-
ments to determine which of these SP fragments, if any, are
present in vivo [36]. SP fragment levels are considerably lower
than that of full-length SP and therefore we included an offline
strong cation exchange (SCX) fraction step prior to the LC-MS/
MS to improve our sensitivity [37]. Using this workflow, we are
able to detect SP, SP1–9 and SP1–7 in the spinal cord. We also
performed an isotope dilution-mass spectrometry (IDMS) exper-
iment to confirm these results. In these experiments, synthetic
stable isotope-labeled versions of SP, SP1–10,S P 1–9,S P 1–8 and
SP1–7 are added into the mixture at known concentrations during
peptide extraction from spinal cords. These labeled synthetic
compounds are easily distinguishable from endogenous SP by mass
spectrometry, and the ratio of the stable isotope-labeled peptides
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concentration of the SP peptides in the spinal cord. IDMS
revealed that the endogenous levels of SP, SP1–9 and SP1–7 were
105.968.5 pmol/g, 2.160.5 pmol/g, and 1.660.5 pmol/g,
respectively (Table 1). We did not detect SP1–10 or SP1–8 in any
of these experiments, suggesting that these peptides are not
generated in vivo.
The primary SP-degrading enzyme is a metallopeptidase
To identify the enzyme class that mediates SP processing we
relied on a screen using class-specific peptidase inhibitors coupled
to quantitative MS analysis. The inhibitors used in this screen
include compounds such as the metallopeptidase inhibitor O-
phenanthroline [42] and PMSF, a serine peptidase inhibitor [43].
We assayed these compounds to test their ability to prevent the SP
degradation and inhibit the production of SP1–9 and SP1–7 in
mouse spinal cord lysates (Fig. 2). Lysate samples were heated (i.e.
heat-treated) to denature all proteins and this served as a control
for complete protease inactivation.
O-phenanthroline inhibited the degradation of SP to the largest
extent with SP values twice as high as the vehicle control,
indicating that a metallopeptidase contributes the most to SP
processing in these tissue lysates. Modest increases in SP levels
were also seen for pepstatin and PMSF, but these differences were
not statistically significant. O-phenanthroline was also the
strongest inhibitor of SP1–9 production, and the overall pattern
of SP1–9 production correlates with the inhibitor specificity for SP
degradation. Specifically, O-phenanthroline was the best inhibitor
but pepstatin and PMSF had a small effect on SP1–9 production.
The correlation between SP1–9 production and SP degradation
indicates that the conversion of SP to SP1–9 may be the key step in
the conversion of SP in spinal cord lysates. By contrast, the
inhibitor sensitivity of SP1–7 production is markedly different from
that of SP degradation.
Contribution of reported SP-degrading enzymes to the
production of SP1–9
Having characterized the conversion of SP to SP1–9 as the key
step in SP degradation, we turned our attention toward the
identification of a chemical inhibitor of this step. SP is often used
as a model substrate for peptidases and proteases and therefore
there are a number of metallopeptidases reported to cleave SP and
produce SP1–9 [29,44–48]; however, to our knowledge these
enzymes have never been shown to control SP levels in vivo. We
reasoned that inhibitors that target these metallopeptidases, even if
they are not specific for these proteins, would provide a good
chance of finding a compound that could influence SP processing
in tissue lysates. The MEROPS database is an authoritative
catalogue of all known peptidases and it includes detailed
information on peptidase substrate specificity [38].
Using the MEROPS database, we identified eight mammalian
peptidases reported to cleave SP to produce SP1–9 (Fig. 3). These
enzymes are all membrane-associated metallopeptidases and are
present in the mouse spinal cord [49,50]. A total of seven
metalloprotease inhibitors that target these enzymes were identi-
fied with the help of the MEROPS [38] and BRENDA databases
[51] (see Materials and Methods). We do not believe any of these
inhibitors are selective and therefore we are using these
compounds as probes to inhibit the conversion of SP rather than
to identify a specific enzyme. For example, the inhibitor actinonin
only inhibits meprin 1A [52] but it is also a matrix metalloprotease
(MMP) inhibitor, and phosphoramidon inhibits at least two of the
candidate enzymes, NEP and ECE-2 (Fig. 3) [53,54].
Each of these inhibitors was added to spinal cord membrane
lysate along with SP. After incubation, the relative levels of SP and
SP1–9 were assessed in the presence of each inhibitor. This assay
Table 1. Absolute quantities of SP and SP fragments in the
spinal cord as measured by isotope dilution mass
spectrometry (IDMS).
Peptides SPC (pmol/g)
SP 105.968.5
SP1–10 n.d.
SP1–9 2.160.5
SP1–8 n.d.
SP1–7 1.660.5
doi:10.1371/journal.pone.0068638.t001
Figure 2. Metallopeptidase inhibitors potently block SP
degradation in spinal cord lysates. A) Different class-selective
inhibitors were tested for their ability to slow SP degradation in spinal
cord membrane lysates. The most effective compound at inhibiting SP
degradation in this assay is O-phenanthroline, a metalloprotease
inhibitor. B) O-phenanthroline was also the most potent inhibitor of
SP1–9 production in these experiments. C) Multiple class-selective
inhibitors regulate SP1-7 production including O-phenanthroline,
pepstatin A and PMSF. (Statistical significance calculated by a Student’s
t-test; p-value ,0.05, *; p-value ,0.01, **; p-value ,0.001, ***, N=4).
doi:10.1371/journal.pone.0068638.g002
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formation of SP1–9: phosphoramidon, actinonin and the MMP
inhibitor GM6001 [55,56]. GM6001 led to the least amount of SP
degradation and strongly inhibited SP1–9 production (Fig. 3).
Specifically, addition of GM6001 results in a nearly 2-fold increase
in SP levels compared to a vehicle, and a greater than 10-fold
decrease in SP1–9 production. In aggregate, this data demonstrates
that GM6001 inhibits a key step in conversion from SP into SP1–9.
Based on the inhibitor sensitivities of SP degradation (Fig. 3)
NEP and ECE-2 are viable SP-degrading enzyme candidates
(Fig. S1). We tested this possibility through several experiments
[35]. First, there was no difference in the processing activity
between tissue lysates from wild type (NEP
+/+) and NEP
–/– mice
[35], indicating that NEP is not the predominant SP-degrading
activity in lysates. Furthermore, NEP
–/– mice had the same spinal
cord concentrations of SP as NEP
+/+ mice to conclusively
demonstrate that NEP does not regulate SP on its own (Fig. 4).
To determine whether ECE-2 is responsible for the SP-
degrading activity we detect in tissue lysates, we solubilized the
proteome with different concentrations of deoxycholate and then
tested these fractions for SP-degrading activity. In addition, we
performed activity assays on each of these fractions to ascertain
whether ECE-2 levels correlate with SP-degrading activity. These
data clearly show that ECE-2 and SP-degrading activity are not
connected and this data disfavors any role for ECE-2 in SP-
degradation in tissue lysates (Fig. S2). Finally, additional MMP
inhibitors (TIMP2 and MMP9i) were not active in protecting SP
from degradation either (Fig. 3). These data indicate that none of
the likely GM6001 targets is solely responsible for the C-terminal
processing and that there may exist a yet unidentified GM6001-
sensitive peptidase that regulates SP levels in vivo.
Small-molecule studies with GM6001 demonstrate that
proteolysis regulates SP levels in the spinal cord
Typical approaches for testing enzymes or pathways for a role
in peptide regulation in vivo require the generation of knockout
mice [36]. By using a small-molecule inhibitor approach we
circumvent the need for any knockout animals to greatly expedite
testing the hypothesis that proteolysis regulates SP levels.
Moreover, the use of a small molecule overcomes challenges of
compensation by other enzymes that sometimes plague knockout
studies [57]. Administration of GM6001 was followed by analysis
of SP in the spinal cords after 3 hours. These experiments showed
that SP levels were ,3-fold higher in the mice treated with
GM6001 versus the vehicle treated controls (Fig. 4). Thus, we
discovered an endogenous GM6001-sensitive proteolytic pathway
that regulates SP levels. More importantly, this data confirms the
hypothesis that proteolysis controls endogenous SP levels.
Discussion
The hypothesis that SP is regulated by proteolysis originated
with the earliest discoveries of potent SP-degrading activity in
nervous tissue, which occurred over three decades ago [27,58].
Subsequent work identified numerous peptidases
[28,31,32,40,41,48,59–61] that cleave SP in vitro, but none of
these enzymes has been shown to regulate SP in vivo. Believing that
identifying a true SP-regulating enzyme may depend on clearly
defining the products of endogenous SP metabolism, many
researchers have conducted in vitro experiments in which the
endogenous metabolic environment of the CNS is simulated
[28,30,40,41]. Typically these experiments involve incubating cell
lysates with large amounts of synthetic peptide. Others have
conducted pseudo-in vivo experiments where synthetic peptide is
introduced into a living tissue and the excess metabolites are
collected and analyzed [62]. In these studies, a multitude of
fragments has been detected, among them SP1–9,S P 1–8,S P 1–7,
SP5–11,S P 6–11,S P 7–11 and SP8–11. The data suggests an extremely
complicated picture for SP proteolysis and does not present a clear
path towards elucidating SP regulation.
Recently, we developed an advanced liquid chromatography-
tandem mass spectrometry (LC-MS/MS) peptide profiling strat-
egy to elucidate the proteolysis of bioactive peptides [24,36]. The
power of this approach lies in its ability to peer directly into the
chemical milieu in which endogenous metabolism occurs. In
applying this approach to SP we circumvent the epistemological
worries one may have about the results of in vitro and pseudo-in vivo
studies, which do not perfectly reconstitute endogenous metabo-
lism. We profiled peptides from the mouse spinal cord and
Figure 3. GM6001 is significantly more effective than other
metallopeptidase inhibitors at preventing SP degradation and
conversion of SP to SP1–9. A) Utilizing the MEROPS and Allen Brain
Map databases a number of candidate metallopeptidases in the
nervous system that are capable of cleaving SP to produce SP1–9 are
identified. Inhibitors against these peptidases were then used in lysates
to evaluate their affect on SP degradation and SP1–9 production. B) The
matrix metalloprotease (MMP) inhibitor GM6001 was the most effective
compound at preventing SP degradation. C) GM6001 is also the best
inhibitor of SP1–9 production. (Statistical significance calculated by a
Student’s t-test; p-value ,0.05, *; p-value ,0.01, **; p-value ,0.001, ***,
N=4).
doi:10.1371/journal.pone.0068638.g003
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metabolites of SP. We confirmed these assignments and obtained
the absolute concentrations of SP, SP1–9, and SP1–7 in tissues using
isotope dilution-mass spectrometry [63]. Our results were consis-
tent with previously reported concentrations of SP in the spinal
cord (,105.9 pmol/g) [64], and demonstrated that SP1–9 and
SP1–7 are approximately 50-fold lower in concentration than SP
(Table 1). We also performed in vitro degradation experiments and
found that enzyme activity capable of producing SP1–9 and SP1–7
resides in the membrane fraction but not the soluble fraction of
spinal cord lysate (Fig. 1). This finding is consistent with the notion
that SP processing occurs outside the cell, where the SP is exposed
to membrane-bound proteases. The combination of in vitro and in
vivo peptide profiling indicates that SP1–9 and SP1–7 are the
primary endogenous products from processing of SP in the spinal
cord.
A series of lysate experiments with class selective inhibitors
showed that SP is regulated by a metallopeptidase and that the
levels of SP and SP1–9 are inversely correlated (Fig. 2). This
indicates that SP degradation is coupled to SP1–9 production and
that the conversion of SP to SP1–9 is a major means of SP
degradation since the inhibition of this pathway affects SP levels.
The results with SP1–7 were less clear, as several inhibitors affected
SP1–7 production and there was no clear correlation between SP1–
7 production and SP levels. We subjectedSP1–9 to degradation in
spinal cord lysates and observed that SP1–7 was produced (Fig. S3).
We reasoned that inhibition of SP1–9 production will reduce SP1–7
levels and therefore focused on the conversion of SP to SP1–9 as
the key step in SP catabolism.
At this point, a typical approach would call for the identification
of the enzyme responsible for this step followed by perturbation of
the protein in vivo to verify the identification [36]. However,
recognizing that the generation of knockout animals is very slow
and often confounded by compensatory effects that mask the
function of the enzyme in knockout animals [57] and that knowing
the identity of the degrading enzyme is not necessary to evaluate
whether SP is regulated by proteolysis, we opted to perform a
small screen of metalloprotease inhibitors to identify a compound
that could potentially be used to perturb the pathway in vivo. In this
way we discovered that GM6001 potently blocks the conversion of
SP to SP 1–9in tissue lysates (Fig. 3).
Fortuitously, GM6001 is bioavailable and had previously been
shown to permeate the central nervous system (CNS) [65]. This
allowed us to test whether GM6001 can influence SP levels in vivo.
Administration of GM6001 to mice resulted in a 3-fold increase in
SP levels in the spinal cord (p-value ,0.001, Fig. 3). While this
strategy does not identify any specific enzyme, it quickly reveals
whether blocking proteolysis regulates SP levels and proves correct
the long-standing hypothesis that SP levels are regulated by
proteolysis. Moreover, given this data the enthusiasm for pursuing
a SP degrading enzyme is increased and GM6001 can be used as a
valuable tool in the discovery of such an enzyme. GM6001 was
previously developed into an activity-based probe that targets
metalloproteases [66] and this unbiased strategy can be applied to
the discovery of a candidate SP-degrading enzyme.
Conclusions
We expect the strategy described herein to be applicable to all
bioactive peptides [67] and we envision the power of the approach
increasing with larger chemical libraries and faster high-through-
put lysate assays. Thus, this work advances the methodology for
the discovery of bioactive peptide regulatory pathways, provides a
chemical inhibitor to study SP regulation in vivo and conclusively
demonstrates that proteolysis plays a major role in the regulation
of SP.
Supporting Information
Figure S1 Flow chart outlining the strategy used at each
step to identify or eliminate a candidate SP-degrading
enzyme. Ultimately this approach identified a GM6001-sensitive
pathway in the spinal cord to validate the hypothesis that
proteolysis regulates SP levels.
(PNG)
Figure S2 ECE2 is not responsible for SP-degrading
activity in lysates. Fractionation of spinal cord lysate by
successive solvation in the detergent deoxycholate coupled with an
LCMS-based assay for SP 1–9 production shows that ECE2
abundance does not correlate with the activity of interest.
(PNG)
Figure 4. SP is regulated by proteolysis but not by NEP. A) Phosphoramidon slows SP1–9 production in tissue lysates, which suggests that NEP
might have a role in SP processing. Experiments in NEP
+/+ and NEP
–/– spinal cord lysates reveals no significant difference in SP degradation. B)
Likewise, no difference in endogenous SP levels is observed in spinal cords from NEP
+/+ and NEP
–/– mice. C) Acute treatment of mice with GM6001
results in a 3-fold elevation of SP in the spinal cord to reveal a GM6001-sensitive pathway for SP regulation. (Statistical significance calculated bya
Student’s t-test; p-value ,0.001, ***, N=4).
doi:10.1371/journal.pone.0068638.g004
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cord lysates that converts SP 1–9 to SP1–7.S P 1–7 is
produced when SP 1–9 is incubated in spinal cord lysate
indicating the presence of a SP1–9 to SP1–7 activity.
(PNG)
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